1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Recurrent Medulloblastoma Global Clinical Trials Review, H1, 2014

Recurrent Medulloblastoma Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Recurrent Medulloblastoma Global Clinical Trials Review, H1, 2014" provides data on the Recurrent Medulloblastoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Medulloblastoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Medulloblastoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Recurrent Medulloblastoma Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Recurrent Medulloblastoma 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Clinical Trials by G7 Countries: Proportion of Recurrent Medulloblastoma to Oncology Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by Phase 15
In Progress Trials by Phase 16
Clinical Trials by Trial Status 17
Clinical Trials by End Point Status 18
Unaccomplished Trials of Recurrent Medulloblastoma 19
Subjects Recruited Over a Period of Time 20
Clinical Trials by Sponsor Type 21
Prominent Sponsors 22
Top Companies Participating in Recurrent Medulloblastoma Therapeutics Clinical Trials 23
Prominent Drugs 24
Clinical Trial Profiles 25
Clinical Trial Overview of Top Companies 25
Novartis AG 25
Clinical Trial Overview of Novartis AG 25
Eli Lilly and Company 26
Clinical Trial Overview of Eli Lilly and Company 26
Clinical Trial Overview of Top Institutes / Government 27
National Cancer Institute 27
Clinical Trial Overview of National Cancer Institute 27
Children's Oncology Group 29
Clinical Trial Overview of Children's Oncology Group 29
City of Hope National Medical Center 30
Clinical Trial Overview of City of Hope National Medical Center 30
Children's Cancer and Leukaemia Group 31
Clinical Trial Overview of Children's Cancer and Leukaemia Group 31
University of Florida 32
Clinical Trial Overview of University of Florida 32
Five Key Clinical Profiles 33
Appendix 115
Abbreviations 115
Definitions 115
Research Methodology 116
Secondary Research 116
About GlobalData 117
Contact Us 117
Disclaimer 117
Source 118

List of Tables
Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials by Region, 2014* 6
Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Recurrent Medulloblastoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Recurrent Medulloblastoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 10
Recurrent Medulloblastoma Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Proportion of Recurrent Medulloblastoma to Oncology Clinical Trials, G7 Countries (%), 2014* 12
Recurrent Medulloblastoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 13
Recurrent Medulloblastoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 14
Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials by Phase, 2014* 15
Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 16
Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 17
Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 18
Recurrent Medulloblastoma Therapeutics, Global, Withdrawn Clinical Trials, 2014* 19
Recurrent Medulloblastoma Therapeutics, Global, Terminated Clinical Trials, 2014* 19
Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 20
Recurrent Medulloblastoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 21
Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 22
Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 23
Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 24
Recurrent Medulloblastoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 25
Recurrent Medulloblastoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 26
Recurrent Medulloblastoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 27
Recurrent Medulloblastoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Oncology Group, 2014* 29
Recurrent Medulloblastoma Therapeutics Clinical Trials Market, Global, Clinical Trials by City of Hope National Medical Center, 2014* 30
Recurrent Medulloblastoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Cancer and Leukaemia Group, 2014* 31
Recurrent Medulloblastoma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Florida, 2014* 32

List of Figures
Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Recurrent Medulloblastoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 9
Recurrent Medulloblastoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 10
Recurrent Medulloblastoma Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Proportion of Recurrent Medulloblastoma to Oncology Clinical Trials, G7 Countries (%), 2014* 12
Recurrent Medulloblastoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 13
Recurrent Medulloblastoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 14
Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials by Phase (%), 2014* 15
Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 16
Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 17
Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 18
Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 20
Recurrent Medulloblastoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 21
Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 22
Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 23
Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 24
GlobalData Methodology 116

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.